Nabsys to host a CoLab Session in partnership with Hitachi High-Tech America, Inc. and Boston Children's Hospital Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, announces the presentation of eight presentations at the American Society of Human Genetics (ASHG) Annual Meeting taking place on October 14-18, 2025, in Boston, MA. In addition […]

The 20th Annual Night of Hope Gala, co-hosted by A Little Hope and Comfort Zone Camp, will be held in New York City on October 16, 2025 to raise funds for the continued support of children and families grieving the loss of a loved one from suicide or overdose. All proceeds will go towards funding

RTX (NYSE: RTX) will issue its third quarter 2025 earnings results on Tuesday, October 21, prior to the stock market opening. A conference call will take place at 8:30 a.m. ET to discuss the results. The conference call will be webcast live on the company's website at www.rtx.com and will be available for replay following

SureCo, an Individual Coverage Health Reimbursement Arrangement (ICHRA) administrator focused on companies with at least 200 employees, today announced the completion of a $23 million Series A funding round led by Health Velocity Capital, with participation from Kaiser Permanente Ventures. The investment will enable SureCo to scale its technology and team, making it easier for

Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting GlobeNewswire September 30, 2025 BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to

Bamboo Ide8 Insurance Services, LLC. (“Bamboo”), part of White Mountains Insurance Group, Ltd. (NYSE: WTM), and specialty insurer Accredited have announced the completion of the reinsurance program supporting the launch of their new E&S Signature program. This reinsurance placement includes the funding of a multi-year sidecar transaction through Greenshoots Re Ltd. (“Greenshoots Re”) that was

Novo Holdings, SR One and Catalys Pacific co-led the financing Company emerges from stealth to advance lead asset, dotinurad, through global Phase 3 clinical trials Dotinurad is a next-generation, once daily oral, URAT1 inhibitor withpotential for best-in-class safety and efficacy, as supported by extensive clinical data from Japan, China and other Asian markets where the

Workday named Pinnacle Group a 2025 winner of its annual Workday Professional and Business Services Innovation Awards. Announced at Workday Rising earlier this month, these awards honor Workday customers who consistently cultivate improvements across their organization, support and empower their peers, and advance the industry. https://mma.prnewswire.com/media/2784970/Pinnacle_Group_Wins_Innovation_Award_at_Workday_Rising.jpg Pinnacle Group was recognized with the Smart Money Professional

BLA based on data from the global Phase 1/2 CADENZA trial AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of investigational Pivekimab sunirine (PVEK) for treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The submission is based on data from

Rigetti Announces Purchase Orders for Two Quantum Computing Systems Totaling Approximately $5.7 Million GlobeNewswire September 30, 2025 BERKELEY, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, announced today that it has secured purchase orders totaling approximately $5.7 million for two 9-qubit